AI-powered discovery platform EVA™ drives development of a highly selective T-cell engager showing over 90% tumor growth inhibition in pre-clinical studies.
London, 13 November 2025 – AI-powered discovery platform EVA™ drives development of a highly selective T-cell engager showing over 90% tumor growth inhibition in pre-clinical studies.
LabGenius Therapeutics, a London-based drug discovery company, is preparing to showcase major progress in next-generation antibody therapies. The company will present new pre-clinical data at the ESMO Immuno-Oncology Congress 2025, taking place December 10–12 at the Queen Elizabeth II Centre in London. The presentation highlights strong in vivo results for LabGenius’ lead bispecific T-cell engager (TCE), which demonstrated more than 90% tumor growth inhibition along with a favorable tolerability profile.
A New Class of Smarter, More Selective Cancer Therapies
Bispecific T-cell engagers are designed to direct a patient’s immune cells to attack cancer cells. LabGenius has advanced this concept by developing a TCE with increased tumor selectivity, helping it better differentiate between healthy and diseased cells. This enhanced accuracy is achieved through avidity-driven mechanisms leveraging differences in tumor-associated antigens to improve precision.
The company’s AI-driven discovery platform, EVA™, played a central role in designing and optimizing the molecule. EVA™ integrates artificial intelligence, robotic automation, and synthetic biology to test and refine therapeutic antibodies at scale. With this technology, LabGenius was able to create a TCE with improved potency, manufacturability, and selectivity, key factors for advancing toward clinical development.
A Hybrid Model for Next-Generation Drug Discovery
LabGenius Therapeutics operates a hybrid approach: collaborating with pharmaceutical and biotech partners while also building its own internal therapeutic pipeline. This structure allows the company to apply its platform across a range of targets, accelerating the discovery of novel multispecific antibodies for solid tumors.
The upcoming presentation at ESMO IO marks an important milestone for LabGenius as it demonstrates both the strength of its platform and the promise of its lead candidate in shaping future immuno-oncology treatments.
